Using Injectable NanoGels to Target Precise Anticancer Drugs in Solid Tumours

Brent Samimi^*
*Correspondence: Brent Samimi, Department of Pharmacy, University of Illinois, Chicago, IL 61820, USA, Email:

Keywords

Nanogels • Microenvironment • Anticancer drugs • Tumor

Introduction

Solid tumors are a heterogeneous group of cancers that form masses of abnormal cells in various tissues, such as the breast, lung, prostate, and liver. Unlike liquid tumors, which include cancers of the blood, solid tumors create formidable obstacles for drug delivery due to their complex microenvironment. These obstacles include dense Extracellular Matrix (ECM), poor blood supply, high interstitial fluid pressure, and the presence of a wide range of cell types, including cancer cells, fibroblasts, immune cells, and blood vessels. All these factors contribute to the difficulty in achieving effective drug delivery to the tumor site. Conventional cancer treatments, such as chemotherapy and radiation therapy, have been the primary strategies for combating solid tumors. However, these treatments have significant limitations. Chemotherapy drugs are typically administered systemically, meaning they circulate throughout the entire body, affecting not only cancer cells but also healthy cells. This often leads to severe side effects, such as nausea, hair loss, and immunosuppression, which can be debilitating for patients. Furthermore, the heterogeneous nature of solid tumors can result in some cancer cells being resistant to chemotherapy, leading to treatment failure. Radiation therapy, on the other hand, can damage surrounding healthy tissue while targeting the tumor, leading to long-term side effects and complications [1].

Literature Review

Injectable Nanogels represent a groundbreaking approach to improving the precision and effectiveness of anticancer drug delivery to solid tumors. These nano-sized hydrogel particles can be loaded with various anticancer drugs and designed to release their payload specifically at the tumor site, overcoming many of the challenges associated with traditional cancer treatments. The primary advantage of injectable Nanogels is their ability to deliver drugs directly to the tumor site, minimizing exposure to healthy tissues. This targeted approach enhances the therapeutic effect while reducing systemic side effects. Nanogels protect the encapsulated drugs from degradation and premature release, ensuring that the drug reaches the tumor site in its active form. Many anticancer drugs have low solubility, making their delivery challenging. Nanogels can improve drug solubility, facilitating their transport through the bloodstream [2].

Nanogels can be engineered to release drugs gradually over time, maintaining a sustained therapeutic concentration at the tumor site. By ensuring a continuous supply of the drug to the tumor, injectable Nanogels can help overcome drug resistance issues often encountered in cancer treatment. Targeted drug delivery reduces the exposure of healthy tissues to cytotoxic drugs, minimizing side effects and improving patients' quality of life. Nanogels exploit the unique properties of solid tumor vasculature. These blood vessels have leaky junctions and impaired lymphatic drainage, allowing Nanogels to accumulate selectively within the tumor due to the EPR effect. Functionalized Nanogels can be engineered to target specific molecules or receptors overexpressed on the surface of cancer cells. This active targeting further enhances the specificity of drug delivery. Some Nanogels respond to environmental cues within the tumor microenvironment, such as changes in pH or enzyme activity. This responsive release mechanism ensures that drugs are released precisely when and where they are needed [3].

Discussion

Nanogels can be designed to encapsulate drugs like paclitaxel and doxorubicin, which are commonly used in breast cancer treatment. Targeted delivery to breast tumors reduces side effects and enhances therapeutic outcomes. Inhalable Nanogels can be used to deliver lung cancer drugs directly to the tumor site, minimizing systemic exposure and improving drug effectiveness. Pancreatic tumors are notoriously difficult to treat due to their location and dense microenvironment. Injectable Nanogels can improve the delivery of chemotherapeutic agents to these tumors. Targeted drug delivery using Nanogels can increase the precision of treatment for prostate cancer while reducing side effects like urinary incontinence and erectile dysfunction [4]. Nanogels can be engineered to target liver tumors, allowing for the selective release of drugs like sorafenib or doxorubicin within the tumor tissue. The safety profile of Nanogels, including potential toxicity and immune responses, requires comprehensive evaluation to ensure their clinical applicability. Scaling up the production of Nanogels for clinical use remains a logistical challenge. Developing efficient and cost-effective manufacturing processes is essential.

Obtaining regulatory approvals for novel drug delivery systems can be a lengthy and complex process. Collaborations between researchers, pharmaceutical companies, and regulatory agencies are crucial. Cancer remains one of the most challenging health issues worldwide, with millions of lives affected by this devastating disease every year. Conventional cancer treatments, such as chemotherapy and radiation therapy, often come with severe side effects and limited effectiveness, primarily due to their inability to target cancer cells specifically [5]. To address these challenges, researchers have been exploring innovative drug delivery systems, and one promising avenue is the use of injectable Nanogels. These nanoscale carriers offer a means to deliver anticancer drugs with pinpoint accuracy to solid tumors, significantly improving treatment outcomes while minimizing collateral damage to healthy tissues. Solid tumors, as opposed to liquid tumors like leukemia, are characterized by the uncontrolled growth of abnormal cells within a particular tissue or organ. These tumors can develop in various parts of the body, including the breast, lung, colon, and brain. Their growth is often accompanied by the formation of a complex network of blood vessels, known as angiogenesis, to supply the tumor with essential nutrients and oxygen. This intricate network can make drug delivery to solid tumors particularly challenging.

Traditional cancer treatments, like systemic chemotherapy, can have profound side effects because they are administered throughout the body. This widespread distribution of drugs leads to damage to healthy tissues and organs, causing severe adverse effects such as nausea, hair loss, and compromised immune function. Furthermore, the heterogeneity within solid tumors, with various cell types and structures, makes it challenging for drugs to penetrate and effectively target all cancerous cells. Nanogels are an emerging technology that holds great promise in the field of cancer therapy. These tiny gel-like structures, typically ranging from 1 to 100 nanometers in size, can encapsulate anticancer drugs and be precisely targeted to solid tumors. Let's explore how these injectable Nanogels work and the advantages they offer in the realm of cancer treatment [6].

Conclusion

Injectable Nanogels represent a promising frontier in the battle against solid tumors. Their ability to deliver anticancer drugs with precision, while minimizing systemic side effects, has the potential to revolutionize cancer treatment. As research in this field continues to advance, it is hoped that injectable Nanogels will become a vital tool in the oncologist's arsenal, offering renewed hope to patients facing the challenges of solid tumor cancers. With further investigation, development, and clinical trials, these innovative drug delivery systems may one day lead to more effective and less debilitating treatments for cancer patients worldwide. Injectable Nanogels represent a groundbreaking approach to revolutionize cancer treatment by offering precise drug delivery to solid tumors. Their ability to target tumors while sparing healthy tissues, controlled drug release, and potential for combination therapies make them a compelling option in the fight against cancer. However, further research, development, and rigorous testing are necessary to ensure their safety and effectiveness in diverse cancer types. With ongoing advancements, Nanogels hold the potential to enhance the lives of millions of cancer patients worldwide, offering hope for more effective and tolerable treatments.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Godau, Brent, Sadaf Samimi, Amir Seyfoori and Ehsan Samiei, et al. "A drug-eluting injectable nanogel for localized delivery of anticancer drugs to solid tumors." Pharm 15 (2023): 2255.

   Google Scholar, Crossref, Indexed at

2. Attama, Anthony A., Petra O. Nnamani, Ozioma B. Onokala and Agatha A. Ugwu, et al. "Nanogels as target drug delivery systems in cancer therapy: A review of the last decade." Front pharmacol 13 (2022): 874510.

   Google Scholar, Crossref, Indexed at

3. Zhang, Lin, Jifei Pan, Shibo Dong and Zhaoming Li. "The application of polysaccharide-based Nanogels in peptides/proteins and anticancer drugs delivery." J Drug Target 25 (2017): 673-684.

   Google Scholar, Crossref, Indexed at

4. Xiong, Meng-Hua, Yan Bao, Xiao-Jiao Du and Zi-Bin Tan, et al. "Differential anticancer drug delivery with a Nanogel sensitive to bacteria-accumulated tumor artificial environment." ACS Nano 7 (2013): 10636-10645.

   Google Scholar, Crossref, Indexed at

5. Allyn, Megan M, Richard H. Luo, Elle B. Hellwarth and Katelyn E. Swindle-Reilly. "Considerations for polymers used in ocular drug delivery." Front Med (Lausanne) 8 (2022): 787644.

   Google Scholar, Crossref, Indexed at

6. Zhang, Yi, Pere Dosta, João Conde and Nuria Oliva, et al. "Prolonged local in vivo delivery of stimuli‐responsive nanogels that rapidly release doxorubicin in triple‐negative breast cancer cells." Adv Healthc Mater 9 (2020): 1901101.

   Google Scholar, Crossref, Indexed at